• 1
    Robertson DL, Anderson JP, Bradac JA et al. HIV-1 nomenclature proposal. Science 2000; 288: 5556.
  • 2
    Korber B, Gaschen B, Yusim K, Thakallapally R, Kesmir C, Detours V. Evolutionary and immunological implications of contemporary HIV-1 variation. Br Med Bull 2001; 58: 1942.
  • 3
    Peeters M. Recombinant HIV sequences: their role in the global epidemic. In: KuikenC, FoleyB, HahnB, McCutchanFE, MellorsJW, MullinsJI, SodroskiJ, WolinskyS, KorberB, eds, HIV sequence compendium 2000. Los Alamos: Los Alamos National Laboratory, 2001; 5472.
  • 4
    Hemelaar J, Gouws E, Ghys PD, Osmanov S. Global and regional distribution of HIV-1 genetic subtypes and recombinants in 2004. AIDS 2006; 20: 1323.
  • 5
    Osmanov S, Pattou C, Walker N, Schwardländer B, Esparza J; WHO-UNAIDS Network for HIV Isolation and Characterization. Estimated global distribution and regional spread of HIV-1 genetic subtypes in the year 2000. J Acquir Immune Defic Syndr 2002; 29: 184190.
  • 6
    McCutchan FE. Understanding the genetic diversity of HIV-1. AIDS 2000; 14 (suppl): 3144.
  • 7
    Gao F, Robertson DL, Morrison SG et al. The heterosexual human immunodeficiency virus type 1 epidemic in Thailand is caused by an intersubtype (A/E) recombinant of African origin. J Virol 1996; 70: 70137029.
  • 8
    Van Harmelen J, Wood R, Lambrick M, Rybicki EP, Williamson AL, Williamson C. An association between HIV-1 subtypes and mode of transmission in Cape Town, South Africa. AIDS 1997; 11: 8187.
  • 9
    McCutchan FE, Hegerich PA, Brennan TP et al. Genetic variants of HIV-1 in Thailand. AIDS Res Hum Retroviruses 1992; 8: 18871895.
  • 10
    Subbarao S, Vanichseni S, Hu DJ et al. Genetic characterization of incident HIV type 1 subtype E and B strains from a prospective cohort of injecting drug users in Bangkok, Thailand. AIDS Res Hum Retroviruses 2000; 16: 699707.
  • 11
    Irwin KL, Pau CP, Lupo D et al. Presence of human immunodeficiency virus (HIV) type 1 subtype A infection in a New York community with high HIV prevalence: a sentinel site for monitoring HIV genetic diversity in North America. Centers for Disease Control and Prevention-Bronx Lebanon HIV Serosurvay Team. J Infect Dis 1997; 176: 16291633.
  • 12
    Böni J, Pyra H, Gebhardt M et al. High frequency of non-B subtypes in newly diagnosed HIV-1 infections in Switzerland. J Acquir Immune Defic Syndr 1999; 22: 174179.
  • 13
    Couturier E, Damond F, Roques P et al. HIV-1 diversity in France, 1996–1998. The AC 11 laboratory network. AIDS 2000; 14: 289296.
  • 14
    Balotta C, Facchi G, Violin M et al. ICONA Study Group Increasing prevalence of non-clade B HIV-1 strains in heterosexual men and women, as monitored by analysis of reverse transcriptase and protease sequences. J Acquir Immune Defic Syndr 2001; 27: 499505.
  • 15
    Holguin A, Aracil B, Alvarez A, Barros C, Soriano V. Prevalence of human immunodeficiency virus type 1 (HIV-1) non-B subtypes in foreigners living in Madrid, Spain, and comparison of the performances of the AMPICOR HIV-1 MONITOR version 1.0 and the new automated version 1.5. J Clin Microbiol 2001; 39: 18501854.
  • 16
    Deroo S, Robert I, Fontaine E et al. HIV-1 subtypes in Luxembourg, 1983–2000. AIDS 2002; 16: 24612467.
  • 17
    Kanki PJ, Hamel DJ, Sankalé JL et al. Human immunodeficiency virus type 1 subtypes differ in disease progression. J Infect Dis 1999; 179: 6873.
  • 18
    Kaleebu P, French N, Mahe C et al. Effect of human immunodeficiency virus (HIV) type 1 envelope subtype A and D on disease progression in a large cohort of HIV-1 positive persons in Uganda. J Infect Dis 2002; 185: 12441250.
  • 19
    Alaeus A, Lidman K, Björkman A, Giesecke J, Albert J. Similar rate of disease progression among individuals infected with HIV-1 genetic subtypes A–D. AIDS 1999; 13: 901907.
  • 20
    Tscherning C, Alaeus A, Fredriksson R et al. Differences in chemokine coreceptor usage between genetic subtypes of HIV-1. Virology 1998; 241: 181188.
  • 21
    Palmer S, Alaeus A, Albert J, Cox S. Drug susceptibility of subtypes A,B,C,D. and E human immunodeficiency virus type 1 primary isolates. AIDS Res Hum Retroviruses 1998; 14: 157162.
  • 22
    Hirsch MS, Conway B, D’Aquila RT et al. Antiretroviral drug resistance testing in adults with HIV infection: implications for clinical management. International AIDS Society-USA Panel. JAMA 1998; 279: 19841991.
  • 23
    Loemba H, Brenner B, Parniak MA et al. Genetic divergence of human immunodeficiency virus type 1 Ethiopian clade C reverse transcriptase (RT) and rapid development of resistance against nonnucleoside inhibitors of RT. Antimicrob Agents Chemother 2002; 46: 20872094.
  • 24
    Descamps D, Apetrei C, Collin G, Damond F, Simon F, Brun-Vezinet F. Naturally occurring decreased susceptibility of HIV-1 subtype G to protease inhibitors. AIDS 1998; 12: 11091111.
  • 25
    Suligoi B, Boros S, Camoni L, Lepore D. Notiziario dell’Istituto Superiore di Sanità. 2009; 22, No. 3, (suppl 1): ISSN0394–9303.
  • 26
    Caritas-Migrantes Foundation. Immigrazione. Dossier statistico 2008. XVIII rapporto. Rome: Edizioni Idos, 2008.
  • 27
    Devereux H, Loveday C, Burke A, Dann L, Johnson M, Phillips A. The prevalence of non-B subtype HIV-1 in a London HIV/AIDS outpatient clinic. AIDS 1999; 13: 142.
  • 28
    Monno L, Brindicci G, Lo Caputo S et al. HIV-1 subtypes and circulating recombinant forms (CRFs) from HIV-infected patients residing in two regions of central and southern Italy. J Med Virol 2005; 75: 483490.
  • 29
    Tramuto F, Vitale F, Bonura F, Romano N. Group for HIV-1 Antiretroviral Studies in Sicily. Detection of HIV type 1 non-B subtypes in Sicily, Italy. AIDS Res Hum Retroviruses 2004; 20: 251254.
  • 30
    Snoeck J, Van Dooren S, Van Laethem K et al. Prevalence and origin of HIV-1 group M subtypes among patients attending a Belgian hospital in 1999. Virus Res 2002; 85: 95107.